REDWOOD CITY, Calif., May 29 /PRNewswire-FirstCall/ -- Genomic Health, Inc. today announced two posters to be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, IL, from June 1 - 5, 2007. Following are details for each embargoed session:
- Saturday, June 2, 2007, 2:00 PM - 6:00 PM Abstract #577 Poster presentation: Prospective Multi-Center Study of the Impact of the 21-Gene Recurrence Score (RS) Assay on Medical Oncologist (MO) and Patient (PT) Adjuvant Breast Cancer (BC) Treatment Selection. Presenter: Shelly S. Lo, M.D. - Sunday, June 3, 2007, 2:00 PM - 6:00 PM Abstract #526 Poster presentation: Prognostic Utility of the 21-Gene Assay in Hormone Receptor (HR)-Positive Operable Breast Cancer and 0-3 Positive Axillary Nodes Treated with Adjuvant Chemohormonal Therapy (CHT): An Analysis of Intergroup Trial E2197. Presenter: Lori J. Goldstein, M.D.
About Genomic Health
Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX(TM), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in a large portion of early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit www.genomichealth.com.
Genomic Health, Inc.CONTACT: Investors, Brad Cole, +1-650-569-2281,investors@genomichealth.com, or Media, Emily Faucette, +1-650-569-2824, ormedia@genomichealth.com, both of Genomic Health
Web site: http://www.genomichealth.com//
